Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (2054)	3/31/2004 5:22:26 PM
From: Ian@SI	Read Replies (1) \| Respond to of 3044

Hi Erik, Isn't this the first publication of a statistically significant result for Velcade treating a solid tumour? And if so, is there an obvious reason why the street seems to be ignoring it? e.g. - Was this just an in vitro test and is still years away from the clinic??? Thanks, Ian Treatment with butyrate alone resulted in minimal apoptosis, but combined histone deacetylase and proteasome inhibition increased apoptosis 3- to 4-fold (P =.02). ... might represent a novel treatment strategy for patients with non-small cell lung cancer.